The presentation of full Phase II data for Pfizer Inc.’s failed serotonin 5-HT6 antagonist PF-05212377 at the Alzheimer’s Association International Conference is disappointing, but still leaves room for others in the class to succeed, like Lundbeck Inc.’s idalopirdine and Axovant Sciences Ltd.’s RVT-101, now dubbed intepirdine.
Full Monty On Pfizer’s Failed 5-HT6 Alzheimer’s Drug Leaves Hope For Class
Presentation of data at Alzheimer’s Association International Conference highlights failure of Pfizer’s 5HT6 antagonist PF-05212377, while still leaving room to hope for others in class like Lundbeck’s idalopirdine and Axovant’s RVT-101
